
    
      The protocol-specified futility criteria were met at the second interim analysis dated 15 Aug
      2012 for OSI-774-205. Per the Data Monitoring Committee's recommendation and FDA's agreement,
      the enrollment of patients in that study and Study OSI-774-206 was permanently closed.
    
  